Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver

Fatty Liver Clinical Trial

Official title:

Hepatic Enzymes and Metabolic-Risk Factors Responses to Laser Acupuncture Versus Cupping Therapy in Fatty Liver

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05623930
• Other study ID #: P.T.REC/012/004116
• Status: Recruiting
• Phase: N/A
• Start date: October 12, 2022
• Est. completion date: April 1, 2023

Study information

• Verified date: November 2022
• Source: Cairo University
• Contact: Ali Ismail, lecturer
• Phone: 02 01005154209
• Email: ali.mohamed[@]pt.cu.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)

Description:

In fatty liver patients,applied cupping (with scarification) will be compared, regarding its effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: April 1, 2023
• Est. primary completion date: April 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 55 Years

Eligibility

Inclusion Criteria:

• fatty liver obese patients Exclusion Criteria: thoracic diseases heart diseases kidney diseases

Related Conditions & MeSH terms

• Fatty Liver

Intervention

Device:
• laser acupuncture
In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian

Other:
• wet cupping
in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.

Locations

Country	Name	City	State
Egypt	Cairo Unoversity	Giza

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	high density lipoprotein	it is a component of lipid profile	12 weeks
Secondary	cholesterol	it is a component of lipid profile	12 weeks
Secondary	low density lipoprotein	it is a component of lipid profile	12 weeks
Secondary	triglycerides	it is a component of lipid profile	12 weeks
Secondary	blood glucose	fasting level of blood glucose will be measured	12 weeks
Secondary	C reactive protein	high sensitivity levels C reactive protein will be measured	12 weeks
Secondary	Malondialdehyde	it ts oxidative stress marker	12 weeks
Secondary	aspartate transaminase	it is a hepatic enzyme that reports the functions of liver	12 weeks
Secondary	alanine transaminase	it is a hepatic enzyme that reports the functions of liver	12 weeks
Secondary	systolic blood pressure	it will be measured by sphygmomanometer	12 weeks
Secondary	diastolic blood pressure	it will be measured by sphygmomanometer	12 weeks
Secondary	pulse rate	it will be measured manually	12 weeks